Spera Pharmasperawas Spun Out From Takeda Pharmaceuticals And Became A Wholly Owned Subsidiary Of Bushu Pharmaceuticals On July 12017 In Osakajapan On March 22020Iwaki & Co Ltd Acquired Spera From Bushu The Iwaki Group Transitioned To A Holding Company Structure Under The New Nameastena Groupon June 12021 Spera Has About 250 Employees Including Researchers And Technical Specialists In The Areas Of Process Chemistryformulationand Analysiswhose Prior Work With Takeda Gave Them Broad Exposure To All Aspects Of Pharmaceutical R&Dmanufacturingand Life Cycle Management Across Myriad Pharmaceutical Products And Therapeutic Areas They Are Engaged In Contract R&D And Manufacturing Of Pharmaceuticals For The Pharmaceutical And Biotech Industry Spera Provides A Wide Offering Of Services As A Cdmo To Meet Its Customersneeds Across The Cmc Spectrumincluding Api And Drug Product Process Development And Cgmp Manufacturinganalytical Method Developmenttechnology Transferand Regulatory Filings Spera Works With Its Clients On Pharmaceutical Technology As Well As R&D Strategy From Early Stages Of Drug Development Through To New Drug Application And Launch With The Acquisition Of Jitsubo Co Ltd In April Of 2021Spera Pharma Can Now Also Offer Jitsubo S Unique Liquid Phase Peptide Manufacturing Technologymolecular Hivinga Cto Its Clientsspera S Cmc Capabilities Therapeutic Area Agnostichowevermost The Company S Current Clients Are Focused On Oncologyimmuno Oncologycnsimmunologyand Rare Diseases The Company Believes That Their Expertise In These Areas Enables Them To Deliver Molecules More Rapidly To Their Partners Spera Intends To Continually Expand Its Efforts Into Other Therapeutic Areas With High Unmet Needs
